Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Gains from Investment Securities: 2024-2025

Historic Gains from Investment Securities for CG Oncology (CGON) over the last 1 years, with Mar 2025 value amounting to $859,000.

  • CG Oncology's Gains from Investment Securities rose 42850.00% to $859,000 in Q1 2025 from the same period last year, while for Sep 2024 it was $7.7 million, marking a year-over-year change of. This contributed to the annual value of $221,000 for FY2023, which is N/A change from last year.
  • According to the latest figures from Q1 2025, CG Oncology's Gains from Investment Securities is $859,000, which was down 88.86% from $7.7 million recorded in Q3 2024.
  • In the past 5 years, CG Oncology's Gains from Investment Securities ranged from a high of $7.7 million in Q2 2024 and a low of $2,000 during Q1 2024.
  • Moreover, its 2-year median value for Gains from Investment Securities was $4.3 million (2024), whereas its average is $4.1 million.
  • Data for CG Oncology's Gains from Investment Securities shows a peak YoY surged of 42,850.00% (in 2025) over the last 5 years.
  • Over the past 2 years, CG Oncology's Gains from Investment Securities (Quarterly) stood at $7.7 million in 2024, then skyrocketed by 42,850.00% to $859,000 in 2025.
  • Its Gains from Investment Securities was $859,000 in Q1 2025, compared to $7.7 million in Q3 2024 and $7.7 million in Q2 2024.